Compare iShares China Large-Cap ETF (FXI) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Heron Therapeutics Inc — how do they compare? iShares China Large-Cap ETF trades at $34.58, while Heron Therapeutics Inc trades at $0.45 (market cap $84.50M). The key difference: iShares China Large-Cap ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| FXI | HRTX | |
|---|---|---|
52-Week High | $41.75 | $2.02 |
52-Week Low | $31.59 | $0.39 |
Market Cap | — | $84.50M |
Sector | — | Health |
Enterprise Value | — | $182.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares China Large-Cap ETF (FXI) trades at $34.535, up 2.27% on the day, with technical indicators showing a bullish overall signal despite some overbought RSI readings. Recent news highlights China's significant push into AI and electric vehicles, including a reported $295 billion AI infrastructure plan and a 30% NEV fleet target by 2030, which could benefit the large-cap Chinese companies held within the fund.
The outlook for FXI is tied to China's economic policy execution and its success in strategic sectors like AI and EVs. Key opportunities include exposure to state-backed industrial and tech giants, while risks stem from U.S.-China tech rivalry, regulatory shifts, and the potential for Chinese equities to act as a value trap despite apparent undervaluation.
HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.
The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
